Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1214063 Under Two Different Regimens in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1214063 Under Two Different Regimens in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tepotinib (Primary)
  • Indications Colorectal cancer; Nasopharyngeal cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono

    • Most Recent Events

    • 01 Jul 2022 Results of a pooled exposure-efficacy analyses included data from an ongoing phase 2 study (VISION) and 4 completed studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992) investigating 500 mg/day tepotinib in NSCLC harboring METex14 skipping alterations published in the Cancer Chemotherapy and Pharmacology
    • 21 Sep 2020 Results of a pooled analysis of data from from four completed phase I/II studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373) and one ongoing phase II study (VISION, NCT02864992) assessing the relationship between tepotinib and both safety and efficacy endpoints in patients with solid tumours, presented at the 45th European Society for Medical Oncology Congress
    • 10 Dec 2019 Results published in the Clinical Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top